although it is difficult to obtain clinical proof that there is no cross-resistance between ifo and cyc , ifo has been shown to be active in multirefractory malignant lymphomas , in small cell lung cancer not responding to adriamycin , vincristine , and etoposide , and in soft tissue and bone sarcomas .
C0010583
cyc
C0020823
ifo